Kenvue Stockholders Overwhelmingly Approve Kimberly-Clark Merger Agreement
KVUE sits 23% above its 52-week low of $14.02.
Summary
Kenvue Inc. announced that its stockholders overwhelmingly approved the merger agreement with Kimberly-Clark Corporation, advancing the acquisition process.
Key Events · M&A and Partnerships · KVUE
-
Merger Agreement Approved
Kenvue stockholders approved the Agreement and Plan of Merger with Kimberly-Clark Corporation, with 1,489,923,158 votes (approximately 99% of votes cast) in favor.
-
Advisory Compensation Approved
Stockholders also approved, on a non-binding advisory basis, the compensation for named executive officers related to the merger transactions.
-
Next Steps for Merger
The transaction is expected to close in the second half of 2026, pending regulatory approvals and other customary closing conditions.
Analysis · KVUE · Life Sciences
Kenvue Inc. stockholders have officially approved the merger agreement with Kimberly-Clark Corporation, marking a critical step towards the completion of the acquisition. This follows previous disclosures, including a Rule 425 filing on January 27, 2026, which indicated strong preliminary shareholder support. The overwhelming approval, with approximately 99% of votes cast in favor, reinforces investor confidence in the strategic combination. While the transaction is still subject to regulatory approvals and other customary closing conditions, this shareholder vote removes a significant hurdle and keeps the merger on track for its expected close in the second half of 2026. Investors should now monitor progress on regulatory clearances.
At the time of this filing, KVUE was trading at $17.22 on NYSE in the Life Sciences sector, with a market capitalization of approximately $33B. The 52-week trading range was $14.02 to $25.17. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.